ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 187,65
0,69%
Dow Jones
39 387,76
0,85%
DAX
18 686,60
1,07%
Brent Oil
83,96
0,48%
Bitcoin
62 487,29
2,12%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. USOTC
  6. EPIRUS Biopharmaceuticals Inc (CE) (EPRSQ)

  7. EPIRUS Biopharmaceuticals Inc (CE) (EPRSQ) Actualités

EPRSQ

EPIRUS Biopharmaceuticals (CE) (EPRSQ)

EPIRUS Biopharmaceuticals Inc (CE)
De:
Trier par:
 Showing the most relevant articles for your search:USOTC:EPRSQ
DateHeureSourceTitreSymboleSociété
14/02/201718h06Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)USOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
26/09/201615h34Edgar (US Regulatory)(25-NSE)USOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
01/08/201619h41Edgar (US Regulatory)Current Report Filing (8-k)USOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
31/05/201622h54Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)USOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
10/05/201623h51Edgar (US Regulatory)Quarterly Report (10-q)USOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
09/05/201622h00GlobeNewswire Inc.EPIRUS Announces Reprioritization of Pipeline to Solely Focus on Biosimilars to Treat Rare Diseases and Key Leadership Change...USOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
29/04/201613h01Edgar (US Regulatory)Amended Annual Report (10-k/a)USOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
29/03/201622h07Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)USOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
29/03/201612h10Edgar (US Regulatory)Annual Report (10-k)USOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
15/03/201621h38Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)USOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
15/03/201611h00GlobeNewswire Inc.EPIRUS Biopharmaceuticals Reports Fourth Quarter and Fiscal Year 2015 Financial Results and Provides Business UpdateUSOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
11/03/201622h08Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)USOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
10/03/201601h46GlobeNewswire Inc.EPIRUS Biopharmaceuticals to Release Fourth Quarter and Fiscal Year 2015 Financial Results and Provide Business UpdateUSOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
01/03/201614h11Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)USOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
09/02/201613h00GlobeNewswire Inc.EPIRUS Biopharmaceuticals Initiates Pivotal Global Phase 3 Clinical Study for BOW015 (Infliximab Biosimilar)USOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
05/02/201622h01GlobeNewswire Inc.EPIRUS Biopharmaceuticals to Participate in Bloomberg Intelligence Healthcare Event on February 12USOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
03/02/201615h00GlobeNewswire Inc.EPIRUS Biopharmaceuticals to Present at LEERINK Partners 5th Annual Global Healthcare ConferenceUSOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
22/12/201520h24Edgar (US Regulatory)Confidential Treatment Order (ct Order)USOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
16/11/201521h38Edgar (US Regulatory)Amended Current Report Filing (8-k/a)USOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
16/11/201512h05GlobeNewswire Inc.EPIRUS Biopharmaceuticals Provides Clinical Program Update on BOW015 (Infliximab Biosimilar)USOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
16/11/201512h00GlobeNewswire Inc.EPIRUS Biopharmaceuticals Reports Third Quarter 2015 Financial Results & Provides Business UpdateUSOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
11/11/201522h05GlobeNewswire Inc.EPIRUS Biopharmaceuticals Reschedules Its Third Quarter 2015 Financial Results Conference Call and WebcastUSOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
10/11/201522h33Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)USOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
10/11/201514h00GlobeNewswire Inc.EPIRUS Biopharmaceuticals Appoints Industry Veteran Vincent E. Aurentz as Chief Business OfficerUSOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
05/11/201514h00GlobeNewswire Inc.EPIRUS Biopharmaceuticals Joins Biosimilars Forum to Help Educate Patients and Healthcare Providers on Importance of Biosimil...USOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
29/10/201512h00GlobeNewswire Inc.EPIRUS Biopharmaceuticals to Release Third Quarter 2015 Financial Results and Provide Business UpdateUSOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
22/09/201502h46GlobeNewswire Inc.EPIRUS Biopharmaceuticals Expands Biosimilar Pipeline and Capabilities Through Acquisition of BiocerosUSOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
20/07/201512h01Edgar (US Regulatory)Notice of Effectiveness (effect)USOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
14/07/201512h00GlobeNewswireEPIRUS Biopharmaceuticals and Polpharma Group Enter Into a Multi-Product, Multi-Region, Profit-Sharing Collaboration to Advan...USOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
13/07/201523h13Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)USOTC:EPRSQEPIRUS Biopharmaceuticals Inc (CE)
 Showing the most relevant articles for your search:USOTC:EPRSQ

Dernières Valeurs Consultées

NASDAQ
MSFT
Microsoft
EU
VIV
Vivendi
EU
CAP
Capgemini
NYSE
MRK
Merck
NYSE
NKE
Nike
NYSE
DIS
Walt Disney
NASDAQ
AMZN
Amazon.com
EU
ML
Michelin
USI
USTECH100
US Tech 100
COIN
BTCUSD
Bitcoin
EU
GLE
Societe Generale
COIN
ETHUSD
Ethereum
EU
CS
Axa
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés